COMMUNIQUÉS West-GlobeNewswire

Bioxodes atteint un premier objectif de recrutement pour l'essai de phase 2a sur l'hémorragie intracérébrale

19/12/2024 - 08:30

Bioxodes a recruté les 16 premiers patients pour l'essai de BIOX-101 Une analyse intermédiaire sera réalisée à la fin du traitement de la première cohorte de patients BIOX-101 est un candidat médicament, first-in-class [...]

Bioxodes meets enrollment milestone in Phase 2a intracerebral hemorrhagic stroke trial

19/12/2024 - 08:30

Bioxodes has enrolled first 16 patients in trial with BIOX-101 Completing treatment of first cohort of patients will trigger interim analysis BIOX-101 is a first-in-class drug candidate, a peptide developed from tick [...]

Tenant compte du décalage des financements non dilutifs à recevoir, CARBIOS décale de 6 à 9 mois les travaux de construction de son usine de biorecyclage du PET de Longlaville

19/12/2024 - 08:45

Tenant compte du décalage des financements non dilutifs à recevoir, CARBIOS décale de 6 à 9 mois les travaux de construction de son usine de biorecyclage du PET de Longlaville Solide position de trésorerie disponible de [...]

Considering delayed non-dilutive sources of financing, CARBIOS postpones construction of its Longlaville PET biorecycling plant for 6 to 9 months

19/12/2024 - 08:45

Considering delayed non-dilutive sources of financing, CARBIOS postpones construction of its Longlaville PET biorecycling plant for 6 to 9 months CARBIOS maintains a robust available cash position of 112 million euros [...]

Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 - CORRECTION

19/12/2024 - 09:37

Oslo, 19 December 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated business combination between the Company and Zelluna [...]

Certa Therapeutics Expands GPR68 Platform through Acquisition of OccuRx

19/12/2024 - 10:00

Strengthened Pipeline Targets Multiple Fibrotic Diseases MELBOURNE, Australia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients [...]

Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

19/12/2024 - 01:08

RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication. RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers, with steroid- [...]

Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia

19/12/2024 - 03:35

Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Shionogi & Co., Ltd. (“Shionogi”) today announce [...]

Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management

18/12/2024 - 22:05

MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of [...]

NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference

18/12/2024 - 22:05

MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management [...]

AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

18/12/2024 - 22:08

VALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]

RemoniHealth Completes 80,000 Remote Monitoring Encounters for Chronic Retina Diseases

18/12/2024 - 22:14

Achieves doubling in remote patient enrollment. Plans Expanded Launch of RH 2.0 Care Management Platform WHITE PLAINS, N.Y., Dec. 18, 2024 (GLOBE NEWSWIRE) -- RemoniHealth, a leading medical technology company providing [...]

Amwell CFO Mark Hirschhorn Expands Leadership Role

18/12/2024 - 22:30

Seasoned leader assumes responsibility for operations and sales as COO BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leader in digital care, has announced Chief Financial Officer (CFO) Mark [...]

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18/12/2024 - 22:30

MALVERN, Pa., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to a new employee as described below. In accordance with NASDAQ Listing [...]

Avid Bioservices Recommends Stockholders Vote FOR Value Maximizing Transaction

18/12/2024 - 22:35

Files Definitive Proxy Statement and Mails Letter to Stockholders TUSTIN, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract [...]

Seegnal Signs Agreement to Install the "Virtual Pharmacist" in a Network of 20 Hospitals in Poland

18/12/2024 - 23:00

TEL AVIV, Israel, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Seegnal eHealth Ltd (“Seegnal” or the “Company”), an Israeli digital health provider, today announced that its Polish distributor recently signed a binding agreement [...]

OSE Immunotherapeutics présentera les résultats d’induction de Phase 2 de l’anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO

18/12/2024 - 18:00

Un abstract clinique sur les résultats d’induction de l’étude de Phase 2 CoTikiS évaluant l’anti-IL-7 récepteur Lusvertikimab dans la rectocolite hémorragique a été accepté pour présentation orale et a été sélectionné [...]

OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO

18/12/2024 - 18:00

A clinical abstract on the induction results from the CoTikiS Phase 2 trial of anti-IL-7 Receptor Lusvertikimab in Ulcerative Colitis accepted for Oral Presentation and selected amongst the Top 10 oral abstracts for 20 [...]

SPINEWAY obtient de nouvelles homologations au Vietnam et enregistre des premières commandes

18/12/2024 - 18:00

Communiqué de presse Ecully, le 18 décembre 2024 – 18h Spineway obtient de nouvelles homologations au Vietnam et enregistre des premières commandes Le groupe Spineway, spécialiste des implants innovants pour le [...]